Analysis of efficacy of combined therapy of amyotrophic lateral sclerosis in mSOD1 transgenic mice model
- Authors: Mukhamedyarov M.A1, Petukhova E.O1, Salafutdinov I.I2, Kuznetsov M.S1, Safiullov Z.Z1, Islamov R.R1, Zefirov A.L1
-
Affiliations:
- Kazan State Medical University
- Kazan (Volga Region] Federal University
- Issue: Vol 15, No 3 (2020)
- Pages: 55-58
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/121981
- DOI: https://doi.org/10.23868/202011008
- ID: 121981
Cite item
Abstract
Full Text
About the authors
M. A Mukhamedyarov
Kazan State Medical University
Email: maratm80@list.ru
E. O Petukhova
Kazan State Medical University
I. I Salafutdinov
Kazan (Volga Region] Federal University
M. S Kuznetsov
Kazan State Medical University
Z. Z Safiullov
Kazan State Medical University
R. R Islamov
Kazan State Medical University
A. L Zefirov
Kazan State Medical University
References
- Brown R.H. Jr., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017; 377(16): 1602.
- Мухамедьяров М.А., Петров А.М., Григорьев П.Н. и др. Боковой амиотрофический склероз: современные представления о патогенезе и экспериментальные модели. Журнал высшей нервной деятельности имени И.П. Павлова 2018; 68(5): 551-67.
- Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2018; 39(2): 733-48.
- Исламов Р.Р., Ризванов А.А., Гусева Д.С. и др. Генная и клеточная терапия нейродегенеративных заболеваний. Клеточная трансплантология и тканевая инженерия 2007; 2(3): 29-38.
- Islamov R.R., Rizvanov A.A., Mukhamedyarov M.A. et al. Symptomatic improvement, increased life-span and sustained cell homing in amyotrophic lateral sclerosis after transplantation of human umbilical cord blood cells genetically modified with adenoviral vectors expressing a neuro-protective factor and a neural cell adhesion molecule. Current Gene Therapy 2015; 15(3): 266-76.
- Islamov R.R., Rizvanov A.A., Fedotova V.Y. et al. Tandem Delivery of Multiple Therapeutic Genes Using Umbilical Cord Blood Cells Improves Symptomatic Outcomes in ALS. Molecular Neurobiology 2017; 54(6): 4756-63.
- Мухамедьяров М.А., Ризванов А.А., Сафиуллов З.З. и др. Анализ эффективности генно-клеточной терапии у трансгенных мышей с фенотипом бокового амиотрофического склероза. Клеточные технологии в биологии и медицине 2012; 4: 215-9.
- Watanabe T., Tanaka M., Watanabe K. et al. Research and development of the free radical scavenger edaravone as a neuroprotectant. Yakugaku Zasshi 2004; 124(3): 99-111.
- Bhandari R., Kuhad A., Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc) 2018; 54(6): 349-60.
- Abe K., Itoyama Y., Sobue G. et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 2014; 15(7-8): 610-7.